All Reports Events Blogs Videos
Showing 175 results
  • See Us At
    July 21, 2026

    Join Sanket Anshuman, Practice Director at Everest Group, to explore how pharmacovigilance (PV) is evolving from a compliance-driven function to an AI-enabled, intelligence-led safety model. Discover how organizations can leverage AI, automation, and real-world data to…
  • Viewpoint
    June 29, 2026

    The post-approval phase represents one of the most complex and strategically critical stages in the life sciences product life cycle, requiring enterprises to ensure continuous safety monitoring, regulatory compliance, and real-world performance optimization. With increasing diverse…
  • Voice of the Customer
    May 13, 2026

    Enterprise AI platforms have become foundational for scaling AI from experimentation to production, as organizations increasingly rely on them to manage model development, deployment, governance, and lifecycle operations across AI workloads. As enterprises navigate growing complexity…
  • Thematic Report
    May 04, 2026

    The global Clinical Research Organization (CRO) market is undergoing a transformation, shaped by rising clinical trial complexity, increasing regulatory requirements, and growing demand for faster, more efficient drug development. CROs continue to play a pivotal role…
  • Viewpoint
    April 28, 2026

    The global safety database market is at an inflection point, driven by increasing complexities in Pharmacovigilance (PV) operations, growing regulatory expectations, and rapid expansion of data sources such as real-world evidence, digital health tools, and patient-generated…
  • Roundtable
    April 16, 2026

    Following our GBS Operating Model FutureCast workshop, Everest Group is convening a select group of GBS leaders for an interactive working session on Thursday, May 07, to pressure test emerging perspectives on reimagining the operating model in the age of agentic AI.  …
  • Roundtable
    March 31, 2026

    Following our GBS Operating Model FutureCast workshop, Everest Group is convening a select group of GBS leaders for an interactive working session on Tuesday, April 14, to pressure test emerging perspectives on reimagining the operating model in the age of agentic AI.  …
  • Blog
    Jan. 13, 2026

    For the past two years, enterprise Artificial Intelligence (AI) strategies have revolved around one central question: which model should we use? Larger, faster, and more fluent foundation models, especially Large Language Models (LLMs), became the focal point of experimentation and investment.  That phase is…
  • Blog
    Nov. 25, 2025

    Artificial Intelligence (AI) is shifting from tools that predict to agents that act. That change doesn’t simply add new software to the stack; it rewires how decisions get made, how work flows across teams, and how value is created.   In that world, the Chief Information…
  • Market Insights™
    Nov. 05, 2025

  • Blog
    Nov. 05, 2025

    In 2006, I visited my first captive center in Bengaluru. At the time, the model was still in its formative years – many multinational organizations were only beginning to explore the potential of setting up their own in-house centers…
  • LinkedIn Live
    Nov. 03, 2025

    As data ecosystems became increasingly complex—with the proliferation of Gen AI and agentic AI implementations—enterprises required real-time visibility into data health, flow, cost, and compliance. Data observability emerged as a strategic layer of trust across digital,…
  • Blog
    Nov. 02, 2025

    The clinical outsourcing market is undergoing a transition with the emergence of specialist-focused Clinical Research Organizations (CROs). A specialist CRO concentrates its expertise in a defined area, such as a therapeutic focus, trial phase or technology, or geographic niche, rather than offering broad,…
  • State of the Market
    Oct. 01, 2025

    The surge in case volumes, more stringent regulatory demands, and therapeutic areas’ rising complexities are significantly transforming pharmacovigilance (PV). As the industry adapts to more tailored reporting requirements and longer patient monitoring periods, enterprises are under…
  • Provider Compendium
    Sep. 30, 2025

    In recent years, life sciences enterprises have reoriented their R&D investments, prioritizing pipeline efficiency and a strategic focus on large and novel molecules. This shift has intensified efforts around cost containment and created a stronger need…
  • Provider Compendium
    Sep. 16, 2025

    Pharmacovigilance (PV) operations have become a strategic priority for life sciences enterprises facing heightened regulatory scrutiny, evolving safety standards, and growing complexity across global markets. This report provides an in-depth assessment of 12 leading PV service…
  • Webinar Deck
    July 31, 2025

    Life sciences commercial teams are facing tighter budgets, faster launch cycles, and growing pressure to prove ROI from every investment and engagement. In this high-stakes environment, a new breed of specialist providers is stepping up, reshaping…
  • Event
    July 29, 2025

    Life sciences commercial teams are facing tighter budgets, faster launch cycles, and growing pressure to prove ROI from every investment and engagement. In this high-stakes environment, a new breed of specialist providers is stepping up, reshaping…
  • LinkedIn Live
    July 24, 2025

    Watch on LinkedIn Global Capability Centers (GCCs) in India rapidly evolved from cost-efficient service hubs to strategic centers of innovation, product development, and digital transformation for global enterprises. As this evolution accelerated, talent development became a…
  • PEAK Matrix®
    July 16, 2025

    In recent years, life sciences enterprises have reprioritized and overhauled their R&D investments. They now focus on streamlining their pipelines and shifting toward new and large molecules. This transformation has compelled aggressive cost containment initiatives, prompting…

Items per page